Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.50 -3.0%	$5.75	$2.90 ▼ $11.16	$283.87M	0.58	3.18 million shs	19.92 million shs
CDTX Cidara Therapeutics	$49.45 +3.0%	$25.04	$10.14 ▼ $56.83	$620.45M	0.79	167,397 shs	3.75 million shs
INMB INmune Bio	$5.33 -15.1%	$7.42	$4.32 ▼ $11.64	$122.50M	1.55	572,941 shs	59.45 million shs
KROS Keros Therapeutics	$13.49 -0.1%	$14.08	$9.12 ▼ $72.37	$547.90M	1.31	864,144 shs	1.57 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	0.00%	-50.34%	-37.61%	-34.21%	-44.04%
CDTX Cidara Therapeutics	0.00%	+135.25%	+124.57%	+120.86%	+341.52%
INMB INmune Bio	0.00%	-16.46%	-27.58%	-29.12%	-26.89%
KROS Keros Therapeutics	0.00%	0.00%	-3.78%	+25.02%	-70.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.2657 of 5 stars	3.5	1.0	0.0	2.9	1.7	0.6
CDTX Cidara Therapeutics	3.7915 of 5 stars	3.6	2.0	4.6	3.1	0.0	0.0
INMB INmune Bio	2.0162 of 5 stars	3.6	0.0	0.0	2.8	1.7	0.6
KROS Keros Therapeutics	4.1017 of 5 stars	4.3	3.0	0.0	2.7	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	3.00	Buy	$19.00	442.86% Upside
CDTX Cidara Therapeutics	3.11	Buy	$55.43	12.09% Upside
INMB INmune Bio	3.17	Buy	$22.80	327.77% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.56	126.51% Upside

Current Analyst Ratings Breakdown

Latest INMB, ALT, CDTX, and KROS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$35.00 ➝ $75.00
6/24/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00 ➝ $68.00
6/23/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $53.00
6/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $54.00
6/23/2025	CDTX Cidara Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$45.00
6/18/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$41.00
6/10/2025	CDTX Cidara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	14,194.25	N/A	N/A	$1.74 per share	2.01
CDTX Cidara Therapeutics	$1.27M	488.66	N/A	N/A	$14.92 per share	3.31
INMB INmune Bio	$10K	12,248.34	N/A	N/A	$1.45 per share	3.68
KROS Keros Therapeutics	$3.55M	154.36	N/A	N/A	$14.11 per share	0.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/6/2025 (Estimated)
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/12/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
KROS Keros Therapeutics	-$187.35M	-$0.18	N/A	N/A	N/A	1.96%	0.75%	0.69%	8/6/2025 (Estimated)

Latest INMB, ALT, CDTX, and KROS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/6/2025	Q1 2025	KROS Keros Therapeutics	-$0.01	$3.62	+$3.63	$3.62	$84.62 million	$211.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	15.85	15.85
CDTX Cidara Therapeutics	N/A	3.87	3.87
INMB INmune Bio	N/A	2.64	2.64
KROS Keros Therapeutics	N/A	19.29	19.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
CDTX Cidara Therapeutics	35.82%
INMB INmune Bio	12.72%
KROS Keros Therapeutics	71.56%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
CDTX Cidara Therapeutics	3.89%
INMB INmune Bio	35.70%
KROS Keros Therapeutics	20.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
CDTX Cidara Therapeutics	90	12.55 million	12.06 million	No Data
INMB INmune Bio	10	22.98 million	14.78 million	Optionable
KROS Keros Therapeutics	100	40.62 million	32.25 million	Optionable

INMB, ALT, CDTX, and KROS Headlines

Recent News About These Companies

B of A Securities Downgrades Keros Therapeutics (KROS)

June 11, 2025 | msn.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

June 11, 2025 | marketbeat.com

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

June 10, 2025 | uk.finance.yahoo.com

3KROS : Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline...

June 10, 2025 | benzinga.com

Activist investor demands Keros 'aggressively' cut costs just weeks after layoffs

June 10, 2025 | fiercebiotech.comF

Keros Therapeutics (NASDAQ:KROS) Rating Lowered to "Neutral" at Bank of America

June 10, 2025 | marketbeat.com

Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders

June 9, 2025 | finanznachrichten.de

Keros To Return $375M to Investors After Shareholder Activism, Safety Signal

June 9, 2025 | biospace.comB

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

June 9, 2025 | prnewswire.com

Keros Therapeutics (NASDAQ:KROS) Shares Gap Down - Here's What Happened

June 9, 2025 | marketbeat.com

Keros Announces Return of $375 Million in Excess Capital to Stockholders

June 9, 2025 | globenewswire.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Boosted by Two Sigma Investments LP

June 9, 2025 | marketbeat.com

Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Keros Therapeutics (KROS)

June 7, 2025 | theglobeandmail.com

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

June 6, 2025 | globenewswire.com

Nuveen Asset Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

June 5, 2025 | marketbeat.com

Keros Therapeutics' (KROS) "Neutral" Rating Reaffirmed at Wedbush

May 31, 2025 | marketbeat.com

Keros Therapeutics Discontinues Cibotercept Development in PAH and Announces Corporate Restructuring

May 30, 2025 | nasdaq.com

After Safety Stumbles, Keros Axes Pulmonary Hypertension Drug, 45% of Staff

May 30, 2025 | biospace.comB

Keros Therapeutics (NASDAQ:KROS) Trading Down 3.9% - Here's What Happened

May 30, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Sells 174,189 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

May 30, 2025 | marketbeat.com

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial

May 29, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Top 3 Silver Picks to Watch as Bull Market Gains Steam
By Chris Markoch | June 18, 2025
View Top 3 Silver Picks to Watch as Bull Market Gains Steam
Hims & Hers Stock: Buy the Dip or Wait It Out?
By Gabriel Osorio-Mazilli | June 5, 2025
View Hims & Hers Stock: Buy the Dip or Wait It Out?
UnitedHealth Stock Dips: Is This a Value Buy Opportunity?
By Jeffrey Neal Johnson | June 13, 2025
View UnitedHealth Stock Dips: Is This a Value Buy Opportunity?
Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet
By Chris Markoch | June 1, 2025
View Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet

INMB, ALT, CDTX, and KROS Company Descriptions

Altimmune NASDAQ:ALT

$3.50 -0.11 (-3.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.47 -0.03 (-0.83%)

As of 06/27/2025 08:00 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Cidara Therapeutics NASDAQ:CDTX

$49.45 +1.42 (+2.96%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$48.14 -1.32 (-2.66%)

As of 06/27/2025 07:39 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

INmune Bio NASDAQ:INMB

$5.33 -0.95 (-15.13%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.42 +0.09 (+1.59%)

As of 06/27/2025 08:00 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Keros Therapeutics NASDAQ:KROS

$13.49 -0.02 (-0.15%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.48 -0.01 (-0.07%)

As of 06/27/2025 05:12 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time